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Microﬂuidic-assisted silk nanoparticle tuning†
Thidarat Wongpinyochit,a John D. Totten,a Blair F. Johnstona and F. Philipp Seib *ab
Silk is nowmaking inroads into advanced pharmaceutical and biomedical applications. Both bottom-up and
top-down approaches can be applied to silk and the resulting aqueous silk solution can be processed into
a range of material formats, including nanoparticles. Here, we demonstrate the potential of microﬂuidics for
the continuous production of silk nanoparticles with tuned particle characteristics. Our microﬂuidic-based
design ensured eﬃcient mixing of diﬀerent solvent phases at the nanoliter scale, in addition to controlling
the solvent ratio and ﬂow rates. The total ﬂow rate and aqueous : solvent ratios were important parameters
aﬀecting yield (1 mL min1 > 12 mL min1). The ratios also aﬀected size and stability; a solvent : aqueous
total ﬂow ratio of 5 : 1 eﬃciently generated spherical nanoparticles 110 and 215 nm in size that were
stable in water and had a high beta-sheet content. These 110 and 215 nm silk nanoparticles were not
cytotoxic (IC50 > 100 mg mL1) but showed size-dependent cellular traﬃcking. Overall, microﬂuidic-
assisted silk nanoparticle manufacture is a promising platform that allows control of the silk nanoparticle
properties by manipulation of the processing variables.
Introduction
Everyday silk from the silk moth (Bombyx mori) is used both in
the textile industry and inmedical applications (most notably as
a surgical suture material).1 Over the past 30 years, a renewed
interest has grown in the silk biopolymer for use in medical
devices, including its recently approved use as a surgical
scaﬀold for supporting and repairing so-tissue damage
in humans.2 Silk is consistently viewed as a promising
biopolymer for biomedical applications across a broad range of
applications.1
Silk has several important and exploitable characteristics,
including (i) excellent mechanical properties, (ii) a long-term
track record of its safe use in humans, (iii) broad biocompati-
bility and biodegradability, (iv) mild aqueous processing
conditions, and (v) the ability to stabilize and protect thera-
peutic payloads (e.g., proteins and small molecular drugs).3,4 In
addition, a reversed engineered silk solution can be processed
into numerousmaterial formats, including hydrogels, scaﬀolds,
lms, microspheres, and nanoparticles (reviewed in5,6). For
these reasons, silk nanoparticles are emerging as interesting
carriers for drug delivery and are now oen proposed for solid
tumor drug targeting.7–10 Silk nanoparticles can be rened—for
example, by surface decorating with polyethylene glycol (PEG)—
to further tailor their performance by improving their colloidal
stability and tuning their immune recognition.8,11 Both native
and PEGylated silk nanoparticles have demonstrated high drug
loading eﬃcacy, pH-dependent drug release, and selective
degradation by protease enzymes as well as by ex vivo lysosomal
enzymes.12
Silk nanoparticles can be manufactured by a broad spectrum
of methods (reviewed in ref. 6 and 13), including poly(vinyl
alcohol) blending (size range 300 nm to 10 mm),14 emulsication
(170 nm),15 capillary microdot printing (25–140 nm),16 salting
out (486–1200 nm),17 supercritical uid technologies (50–100
nm),18 ionic liquid dissolution (180 nm),19 electrospraying (59–
80 nm),20 vibrational splitting of a laminar jet (up to 400 mm),21
electric elds (200 nm to 3 mm),22 milling technologies (200
nm),23 and organic solvent desolvation (35–170 nm).7,8,24,25
Among these methods, the desolvation method for manufac-
ture of silk nanoparticles is a robust and reproducible tech-
nique for the production of stable and uniform nano-sized
particles. This method involves mixing an aqueous silk solution
with a water-miscible organic solvent (e.g., methanol, iso-
propanol, acetone, etc.) to cause the nanoprecipitation of silk
and the formation of silk nanoparticles. However, the current
desolvation methods used to generate silk nanoparticles are
time-consuming batch processes that allow little in-process
control for tuning nanoparticle characteristics such as particle
size. The ability to control the particle size and polydispersity of
nanoparticles designed for drug delivery applications is
important, as these particle attributes aﬀect performance
factors such as loading capacity (and thus drug dosage), tar-
geting capabilities, cellular uptake, and both whole body and
cellular pharmacokinetic characteristics.26
Over the past decade, remarkable progress has been made in
the development of microuidic-based uid handling systems
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that can be applied to particle production for drug delivery
applications (e.g., lipid, solid, tuned shape, etc.). Microuidics
enable the precise manipulation of liquids that allow the control
of process parameters, such as the total ow rate, ow rate ratios
between diﬀerent phases, particle geometry, drug loading, etc.27–29
Nevertheless, despite the advantages of microuidics, few studies
have exploited this technology to generate silk particles. Some
approaches have included glass capillary-based microuidics
(resulting in particles 145–200 mm in size),30 double junction
microuidics (10–200 mm particles)31 and single and double T-
junction droplet microuidics (colloids 5–80 mm).32 However,
these previous studies produced micro-sized particles that are too
large in size for use as carriers in many drug delivery applications
(e.g., tumor targeting following intravenous dosing, endocytic
uptake, intracellular traﬃcking, etc.).
The aim of the current study was therefore to manufacture
silk nanoparticles by desolvation using the NanoAssemblr™
microuidic setup. We investigated the impact of several
process parameters, such as the total ow rate, ow rate ratios
(i.e., aqueous to organic solvent), and organic solvent choices
(acetone and isopropanol) on silk nanoparticle physical char-
acteristics (e.g., yield, particles size, polydispersity, zeta poten-
tial, stability, secondary structure, and morphology). We
manufactured bespoke silk nanoparticles to demonstrate the
impact of silk nanoparticle size on uptake and intracellular
traﬃcking.
Materials and methods
Manufacturing of silk nanoparticles by microuidics
Bombyx mori cocoons were cut into approximately 5  5 mm
pieces and degummed by boiling in 0.02 M Na2CO3 for 60 min.
The degummed bers were then rinsed in ultrapure water and
air-dried. The dry bers were dissolved in 9.3 M LiBr solution at
60 C for up to 4 h and subsequently dialyzed (molecular weight
cut oﬀ 3500 g mol1) against ultrapure water for 48 h to remove
the LiBr salt. The resulting aqueous silk solution was cleared by
centrifugation. A visual protocol format showing reverse engi-
neering of silk cocoons is available.25
Silk nanoparticles were manufactured using a Nano-
Assemblr™ benchtop instrument version 1.5 (model number: SN:
NA-1.5-16) (NanoAssemblr™, Precision Nano-Systems Inc. Van-
couver, Canada) equipped with a microuidic cartridge (product
code: NIT0012) (Fig. 1A). A 3% w/v aqueous silk solution and
organic solvent (either acetone or isopropanol) were injected into
separate chamber inlets, the silk nanoprecipitated in the micro-
uidicmixer, and the resulting nanoparticles were collected in the
outlet (Fig. 1B). The total ow rates of the organic solvent and silk
solution were varied from 1 to 12 mL min1, and the ow rate
ratio was varied at 1 : 1, 3 : 1 and 5 : 1 (Fig. 1C). The collected silk
nanoparticles were centrifuged at 48 400  g for 2 h and the
supernatant was aspirated and discarded. The pellet was
resuspended in ultrapure water, vortexed, and subsequently
sonicated twice for 30 s at 30% amplitude with a Sonoplus HD
2070 sonicator (ultrasonic homogenizer, Bandelin, Berlin, Ger-
many). These centrifugation, washing, and resuspension steps
were repeated at least twice more to produce the nal silk nano-
particle suspension. The nanoparticles were characterized as
detailed below and stored at 4 C until use.
The yield of silk nanoparticles
The total volume of the silk nanoparticle stock suspension was
determined. Next, several 2 mL Eppendorf tubes were weighed
before adding silk nanoparticles (W1). The manufactured silk
nanoparticles were then added, frozen, and lyophilized over-
night. The tubes containing the resulting freeze-dried silk
nanoparticles were weighed again (W2) to determine the
amount of silk nanoparticles and overall yield eqn (1).
Silk nanoparticle characterization and stability in water
The particle size, polydispersity index (PDI), and zeta potential of
silk nanoparticles in ultrapure water were determined at 25 C by
dynamic light scattering (DLS, Zetasizer Nano-ZS Malvern
Instrument, Worcestershire, UK). Particle size was determined
using refractive indices of 1.33 for water and 1.60 for protein. The
silk nanoparticles were stored in water at 4 C and 37 C and the
size, PDI, and zeta potential were determined at days 0, 14, 28, 35,
and 42. All measurements were conducted in triplicate.
Secondary structure measurements of silk nanoparticles
The silk nanoparticle suspension was frozen and then
lyophilized overnight. The samples were subjected to
secondary structure analysis by Fourier transform infrared
(FTIR) spectroscopy (TENSOR II FTIR spectrometer, Bruker
Optik GmbH, Ettlingen, Germany). Each measurement was
run for 128 scans at a 4 cm1 resolution over the wavenumber
range of 400 to 4000 cm1. OriginPro 9.2 Soware was used to
correct the baseline and peak t at the amide I region (1595–
1705 cm1), based on previous analyses.33 Briey, the amide I
region was identied and deconvoluted: 1605–1615 cm1 as
side chain/aggregated strands, 1616–1637 cm1 and 1697–
1703 cm1 as beta-sheet structure, 1638–1655 cm1 as
random coil structure, 1656–1662 cm1 as alpha-helical
bands, and 1663–1696 cm1 as turns. The second derivative
was applied at the amide I region for peak nding. Gaussian
line shapes were used for curve tting. Overtting of the data
was avoided by xing the peak full width at half-maximum
(FWHM) at 10 cm1.
Scanning electron microscopy of silk nanoparticles
The morphology of the prepared silk nanoparticles was
assessed by scanning electron microscopy (SEM) using a FE-
% Yield of the silk nanoparticles ¼
ðW2W1Þ  total suspension volume
amount of silk passed through the microfluidic system volume of sample
 100 (1)
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SEM SU6600 instrument (Hitachi High Technologies, Krefeld,
Germany) at 5 kV. Samples were pipetted onto a silicon wafer
and lyophilized overnight. The specimens were coated with gold
(15 nm thickness) using an ACE200 low vacuum sputter coater
(Leica Microsystems, Wetzlar, Germany). The SEM images were
processed using ImageJ v1.51j8 (National Institutes of Health,
Bethesda, MD).34
Manufacture of silk nanoparticles for in vitro assays
Silk nanoparticles were manufactured by the automated
microuidic NanoAssemblr™ benchtop instrument, as detailed
above. The total ow rate and ratio of isopropanol and 3% w/v
aqueous silk solution were varied depending on the formula-
tions: (i) 5 : 1 at 1 mL min1 for 110 nm size and (ii) 5 : 1 at 12
mL min1 for 215 nm size.
Macrophage responses toward silk nanoparticles
The murine macrophage RAW 264.7 cell line was purchased
from ATCC (Manassas, VA, U.S.A.). Cells were cultured in Dul-
becco's Modied Eagle Medium (DMEM) (4.5 g glucose, 110 mg
sodium pyruvate, 10% v/v FBS), grown in a humidied 5% CO2
atmosphere at 37 C and routinely subcultured every 2–3 days by
scraping cells oﬀ the ask and replating them at a split ratio of
1 : 10 on tissue culture treated polystyrene (Corning, New York,
Fig. 1 Schematic of silk nanoparticles manufacture using a microﬂuidic cartridge coupled with a NanoAssemblr™ benchtop instrument. (A)
NanoAssemblr™ benchtop instrument with major components and arrangement. At front view, number 1 and 3 identify collection tubes for
nanoparticles and waste, respectively. Number 2 and 4 are syringes containing an organic solvent and a 3% w/v silk solution, respectively. (B)
Organic solvent and the silk solution are pumped into two inlets and rapidly three dimensional mixed, which leads to silk nanoparticle formation
by nanoprecipitation. The microﬂuidic cartridge contains a micromixer channel, which is designed as a staggered herringbone structure. (C) The
total ﬂow rate, total ﬂow rate ratio, and solvent choice were the process parameters for this study.
This journal is © The Royal Society of Chemistry 2018 Nanoscale Advances
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NY, U.S.A.). For cytotoxicity studies, cells were seeded in 96-well
plates at a density of 1.5  104 cells per cm2 and allowed to
recover 24 h. Next, cells were treated with 2.5 to 100 mg mL1 of
110 nm and 215 nm silk nanoparticles. Aer a 48 h of incuba-
tion, cell viability was determined using 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT; 5 mg mL1 in
phosphate buﬀered saline (PBS)); 20 mL of MTT was added to
each well and cultures were incubated for 5 h. The formazan
product was solubilized with 100 mL of dimethyl sulfoxide
(DMSO) and absorbance was measured at 570 nm. Untreated
control cells represented 100% cell viability.
For tumor necrosis factor alpha (TNF-a) release, cells were
seeded in Petri dishes at a density of 1.5  104 cells per cm2 and
allowed to recover overnight. Next, the culture medium was
aspirated and replaced with fresh medium containing either (i)
15 ng of lipopolysaccharide (LPS, Sigma-Aldrich, St. Louis, MO,
U.S.A.), (ii) 10 mg mL1 and 500 mg mL1 of either 110 nm or
215 nm silk nanoparticles, and (iii) control medium. Cultures
were incubated for 24 h and then the medium was collected and
centrifuged at 6000  g for 5 min. The supernatants were stored
at 80 C until analysis. Culture supernatants were assayed for
mouse TNF-a using a DuoSet ELISA (R&D Systems, Minneap-
olis, MN, USA) according to the manufacturer's instructions. All
measurements were derived from three biological replicates.
Labeling silk nanoparticles with uorescent probes
A total of 3.5 mg of 110 and 215 nm silk nanoparticles were
uorescently labeled as follows. First, the respective silk nano-
particles were resuspended in 0.2 M NaHCO3 at pH 8.3. Next,
either 1 mg of Alexa Fluor 488 succinimidyl ester or Alexa Fluor
594 succinimidyl ester (Life Technologies, Carlsbad, CA, USA)
was dissolved in anhydrous DMSO at 1 mg mL1. Then, 100 mL
of Alexa Fluor 488 and 100 mL of Alexa Fluor 594 solution were
added, respectively, to 110 nm silk nanoparticles and 215 nm
silk nanoparticles in 0.2 M NaHCO3, pH 8.3. The samples were
allowed to react overnight at room temperature in the dark with
stirring. The labeled silk nanoparticles were then centrifuged,
and the pellets were washed three times with acidied water
(pH 4.6) to remove unbound dye, followed by three washes with
ultrapure water. The samples were stored at 4 C in the dark
until use.
Cellular uptake and intracellular distribution of silk
nanoparticles
RAW 264.7 cells were seeded and cultured in complete DMEM
medium without phenol red. The cells were washed three times
with PBS and the culture medium was replaced with either (i)
control DMEM or (ii) 0.5 mg mL1 mixed Alexa Fluor 488 (Life
Technologies, Carlsbad, CA, U.S.A.) labeled 110 nm silk nano-
particles and Alexa Fluor 594 (Life Technologies, Carlsbad, CA,
U.S.A.) labeled 215 nm silk nanoparticles. The cells were either
(i) incubated for 1 h or (ii) incubated 1 h followed by three
washes with PBS and a 3 h chase in culture medium. The
incubation was stopped by placing the cells on ice, aspirating all
the medium, and washing three times with ice-cold PBS. The
cells were then stained with 1 mg mL1 Hoechst 33342 (Thermo
Scientic, Waltham, MA, USA) for 10 min at room temperature
in the dark, washed three times with ice-cold PBS, and live cells
were imaged immediately with a Leica TCS-SP5 confocal laser
scanning microscope (Leica Microsystems GmbH, Wetzlar,
Germany) equipped with a 40 magnication water objective
with a numerical aperture of 1.25. The data were exported to
ImageJ 1.51j8 (National Institute of Health, U.S.A.)34 for image
analysis and colocalization.
Statistical analyses
Data were analyzed using GraphPad Prism 7.0 (GraphPad
Soware, La Jolla, CA, U.S.A.). Sample pairs were analyzed with
the Student's t-test. Multiple samples were evaluated by One-
way and Two-way analysis of variance (ANOVA) followed by
Bonferroni's multiple comparison post hoc test or Dunnett's
post hoc tests to compare between the control and samples.
Asterisks denote statistical signicance as follows: *P < 0.05, **P
< 0.01, ***P < 0.001. All data are presented as mean values 
standard deviation (SD), and the number of independent
experiments (n) is noted in each gure legend.
Results
The yield of silk nanoparticles
The percentage yield of silk nanoparticles was dependent on
the total ow rate, the solvent ratio, and the actual solvent
used. A solvent : aqueous total (ow rate) ratio of 5 : 1 gave
Fig. 2 Percentage yield of silk nanoparticles produced with
a NanoAssemblr™ benchtop platform by varying the total ﬂow
rate and the ﬂow rate ratios. The percentage yield of silk nano-
particles using the organic solvents (A) acetone, and (B) iso-
propanol. Error bars are hidden in the bar when not visible, SD,
n ¼ 3.
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the best yield for both solvent systems (Fig. 2). The yield of
silk nanoparticles was higher when prepared from iso-
propanol than from acetone, especially at the 1 mL min1
ow rate. The highest silk nanoparticle yield (11.7% w/w of
silk) was obtained from isopropanol with the iso-
propanol : silk (i.e., aqueous phase) ratio of 5 : 1 and a 1
mL min1 ow rate (Fig. 2B).
Silk nanoparticle characterization and their stability in water
For DLS measurement, the overall particle size of silk nano-
particles ranged from 110 nm to 310 nm, with a poly-
dispersity ranging from 0.1 to 0.25 and a negative surface
charge ranging from 20 mV to 30 mV (Fig. 3). The aceto-
ne : aqueous total ow rate ratio of 3 : 1 generated the
smallest size (110 nm), while the acetone : aqueous total ow
rate ratio of 1 : 1 generated larger particles (200 nm) (Fig. 3A).
By contrast, the isopropanol : aqueous ratio of 5 : 1 at a 1
mL min1 ow rate generated the smallest size (110 nm) and
the isopropanol : aqueous total ow rate ratio of 1 : 1 at 12
mL min1 generated the largest particle size (310 nm)
(Fig. 3A). However, a solvent : aqueous ratio of 1 : 1 showed
higher polydispersity (>0.2), indicative of a wider particle size
distribution (Fig. 3B). The solvent : aqueous total ow rate
ratio of 5 : 1 generated higher negative charges of silk
nanoparticles when compared with a lower ratio of solvents
(Fig. 3C).
The particle size stability was also determined for up to 42
days. For the acetone system, all formulations were stable in
water at 4 C for up to 42 days. Silk nanoparticles generated
with a ratio of solvent to silk of 5 : 1 at 12 mL min1 showed
a statistical signicant increase in particle size aer storage
at 37 C for 42 days (Fig. 4). The polydispersity of the silk
nanoparticles did not change at 4 C and 37 C for up to 42
days (Fig. S1†). For the isopropanol system, silk nano-
particles generated with the ratios of solvent : silk of 3 : 1 and
5 : 1 were stable at 4 C and 37 C for up to 42 days. However,
silk nanoparticles generated with a isopropanol : silk ow
rate ratio of 1 : 1, especially at the total ow rate of 12
mL min1, were not stable aer 14 days (Fig. 4). The poly-
dispersity of the silk nanoparticles from an isopropanol : silk
ow rate ratio of 5 : 1 slightly increased aer 28 days
(Fig. S1†). The negative surface charges of the silk nano-
particles from all formulations signicantly decreased aer
14 days at 37 C (Fig. S2†).
Secondary structure measurement
The secondary structure of the silk nanoparticles produced
under diﬀerent process conditions was determined by FTIR
measurement following peak analysis. Overall, silk nano-
particles manufactured using microuidics had a high beta-
sheet content (48–51%), and changes in the microuidic
parameters had no signicant eﬀect on this content (Fig. 5).
Fig. 3 Characterization of silk nanoparticles produced with acetone and isopropanol using a NanoAssemblr™ benchtop platform with diﬀerent
total ﬂow rates and ratios. (A) Particles size (nm), (B) polydispersity index (PDI), and (C) zeta potential of silk nanoparticles. Error bars are hidden in
the bars when not visible, SD, n ¼ 3.
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Scanning electron microscope of silk nanoparticles
The morphology of silk nanoparticles was analyzed by SEM
(Fig. 6). The silk nanoparticles generated by the solvent : aqu-
eous total ow rate ratios of 3 : 1 and 5 : 1 had spherical shapes
and uniform distributions, which correlated with the DLS
measurements. Silk nanoparticles obtained using a total ow
rate ratio of 1 : 1, especially at the total ow rate of 12
mLmin1, showed larger sizes (up to 400 nm), irregular shapes,
and wide particle distributions (particles ranging from 200 nm
to 400 nm) (Fig. 6).
In vitro cytotoxicity and macrophage responses to silk
nanoparticles
For cytotoxicity studies, two diﬀerent sizes of silk nanoparticles
(110 and 215 nm) were generated. No signicant diﬀerences
were noted in cytotoxicity between the two diﬀerent sizes of silk
Fig. 4 Stability of silk nanoparticles manufactured with a microﬂuidic-based method by varying solvents, the total ﬂow rate, and the ﬂow rate
ratios. The particle size of the silk nanoparticles in water at 4 C and 37 C was measured over 42 days. Error bars are hidden in the plot symbols
when not visible, SD, n ¼ 3.
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nanoparticles (Fig. 7A). The half maximal inhibitory concen-
tration (IC50) of 110 nm and 215 nm silk nanoparticles toward
RAW 264.7 cells was >100 mg mL1. The TNF-a release by
macrophages exposed to silk nanoparticles and LPS (positive
control) was also measured (Fig. 7B). TNF-a release in response
to 110 nm silk nanoparticles (at both 10 mg mL1 and 500 mg
mL1) did not diﬀer signicantly from the release by control
cultures. However, treatment of the cells with 500 mg mL1 of
215 nm silk nanoparticles caused a small, but statistically
signicant, increase in TNF-a release when compared to 110 nm
nanoparticles at the equivalent dose (Fig. 7B). There was
a statistical diﬀerence TNF-a release between concentration of
10 mgmL1 and 500 mgmL1 of the silk nanoparticles (Student's
t-test).
Cellular uptake and intracellular distribution of silk
nanoparticles in macrophages
Cellular uptake and intracellular distribution of 110 nm and
215 nm silk nanoparticles were qualitatively studied using live-
cell confocal microscopy (Fig. 8). Following a 1 h pulse, 110 nm
silk nanoparticles and 215 nm silk nanoparticles were inter-
nalized into diﬀerent early endosome compartments. However,
aer a 3 h chase, both sizes of silk nanoparticles were localized
in the same late endocytic compartments. These results were
corroborated by prole plots that showed high co-localization
aer the 3 h chase (Fig. 8).
Discussion
Silk from Bombyx mori has a strong clinical track record1 and is
currently emerging as a promising biomaterial for drug delivery
(e.g., ref. 5, 6 and 35). The manufacture of silk nanoparticles is
now increasingly reported (typically in the 100 nm size range),
oen for (anticancer) drug delivery applications (e.g., ref. 10 and
36). Our use of silk nanoparticles has specically focused on
drug loading and release,7 surface modication,8 intracellular
drug delivery,9 and the degradation of silk nanoparticles in
cells,12 as well as on the impact of these nanoparticles on
metabolism and blood compatability.11,37 However, in all of
these previous studies, we used 100 nm silk nanoparticles that
we fabricated using a “conventional” nanoprecipitation
method; i.e., manually adding the reverse-engineered silk
solution to the organic phase.25 This production method is
a batch-based process and aﬀords no in-process control to ne
tune the particle properties. Therefore, a manufacturing
method that enables rapid silk nanoparticle production while
providing control over the nanoparticle characteristics would
represent a substantial improvement and would open up the
use of these silk nanoparticles in a wider spectrum of biomed-
ical applications.
Microuidic-based technologies have been successfully used
for liposome and nanoparticle production (e.g., using 1,2-
dipalmitoylphosphatidylcholine, phosphatidylcholine, poly-
caprolactone-block-poly(ethylene oxide) and poly(lactide-co-gly-
colide)-b-polyethyleneglycol), which allow scalable production
and control over the particle characteristics.38–41 Many diﬀerent
microuidic platform designs have been introduced, but the
most important feature is the mixer channel layout, which has
included, for example, droplet based42 as well as T and Y shaped
mixers.43,44 The staggered herringbone structure is a highly
eﬃcient micromixer and is now one of the commonest designs,
as it enhances the mixing of the aqueous and solvent phases
due to chaotic advection phenomena.45 The staggered herring-
bone micromixer is the most eﬃcient passive mixer and could
therefore be regarded as a “three dimensional” mixer. The
staggered herringbone design shows higher mixing eﬃciency
when the Reynolds numbers is in a range of 0 < NRe < 1000 (low
NRe). Therefore, mixing eﬃciency declined as Reynolds number
increased with increasing ow rate. In the present study, we
used the fully automated NanoAssemblr™ platform in combi-
nation with a commercially available microuidic chip that
incorporates the staggered herringbone structure design
(Fig. 1).
We believe that this study is the rst to report the continuous
manufacture of silk nanoparticles. The production eﬃciency for
generation of silk nanoparticles showed that the optimal
conditions for achieving the highest silk nanoparticle yields
were a total ow rate at 1 mL min1 at a 5 : 1 solvent : aqueous
ratio (Fig. 2). We speculate that this slower total ow rate (versus
12 mL min1) and high solvent concentration allows more time
for interaction between the aqueous and solvent phases,
thereby enabling a better removal of solvating water from the
silk structure and ultimately resulting in silk nanoparticle
Fig. 5 Secondary structure analysis of silk nanoparticles produced by
microﬂuidics by varying the total ﬂow rate, ﬂow rate ratio, and solvents.
Secondary structure content (%) of silk nanoparticles using (A) acetone
and (B) isopropanol as the organic solvent.
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Fig. 6 Scanning electron microscopy images of silk nanoparticles produced using the NanoAssemblr™ benchtop platform with diﬀerent total
ﬂow rates and ratios of organic solvents (scale bar ¼ 1 mm).
Fig. 7 In vitro cytotoxicity and TNF-a release from macrophages (RAW 264.7 cells) in response to treatment with silk nanoparticles. (A) For
cytotoxicity tests, 2.5 to 100 mgmL1 of 110 nm and 215 nm silk nanoparticles (SNPs) were incubatedwith the cells for 48 h. (B) The TNF-a release
into culture supernatants was quantiﬁed following a 24 h of exposure to 15 ng of LPS (positive control) or 10 mgmL1 and 500 mgmL1 of 110 nm
and 215 nm silk nanoparticles and compared to release by untreated control cells (basal TNF-a levels). Dunnett's post hoc test was used to
evaluate statistical diﬀerences between the basal and the samples. Error bars are hidden in the plot-symbol when not visible, SD, n ¼ 3.
Nanoscale Advances This journal is © The Royal Society of Chemistry 2018
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formation through beta-sheet formation.46 Therefore, solvents
with a high capacity to form hydrogen bonds with water are
predicted to be good candidates for silk nanoparticle formation.
We therefore selected isopropanol (a polar protic organic
solvent), as it has a greater ability than acetone (or DMSO) (a
polar aprotic organic solvents) to form hydrogen bonds with
water. Previous batch-based studies have also successfully used
isopropanol for silk nanoparticle formation (particle size
ranging from 100 to 400 nm).46,47 In the current study, the choice
of a low ow rate of 1 mL min1, the selection of isopropanol,
and the use of a high organic solvent : aqueous ratio (i.e., 5 : 1)
led to signicant improvements in yield (Fig. 2). Both the sol-
vent : aqueous ratio and the ow rate had a signicant impact
on the particle size, PDI, and zeta potential (Fig. 3). The high
solvent : aqueous ratio (i.e., $ 3 : 1) generated small particles
(110–200 nm) with a low polydispersity index (0.1–0.2) and high
negative surface charge (23 to 30 mV). Overall, these data
highlight the importance of using suﬃcient amounts of solvent
to extract the solvating water from the silk to initiate uniform
nanoparticle nucleation and, ultimately, to narrow the particle
size distribution. The zeta potential of silk nanoparticles
produced using the microuidic setup was less negative (20 to
30mV) when compared to those produced by a standard batch
method (40 mV to 50 mV, e.g., ref. 8 and 9). This compara-
tively low negative zeta potential could be a consequence of the
continuous ow during particle formation, which could ulti-
mately result in a diﬀerent packing arrangement.
We also examined silk nanoparticle stability in water over 42
days, because (medical) applications of these silk nanoparticles
requires them to have long-term stability during storage (Fig. 4,
S1 and S2†). Silk nanoparticles generated from microuidics
using a solvent : aqueous total ow rate ratio$ 3 : 1 were stable
at 4 C and 37 C over the entire study period. This nding
conrms the importance of the desolvating solvent concentra-
tion for silk nanoparticle formation and stability, because low
solvent to silk concentration ratios resulted in nanoparticles
with compromised stability. We therefore also expect to see
diﬀerences in secondary structure, because silk nanoparticles
with a low beta-sheet content have been reported.48 However,
the silk nanoparticles prepared by microuidics had a compa-
rable beta-sheet content (Fig. 5), indicating that this content
was independent of the process parameters. Overall, all the silk
nanoparticles generated were highly crystalline and essentially
identical with respect to their secondary structure to nano-
particles we have previously reported.8,9
Morphological assessment by electron microscopy indicated
that the total ow rate and the ow rate ratio were the key
parameters that inuenced the particle appearance (Fig. 6). Silk
nanoparticles generated with a slow ow rate (1 mL min1)
showed a more globular shape and appeared as discrete nano-
particles when compared with those generated using a ow rate
Fig. 8 Impact of silk nanoparticle size on traﬃcking in macrophages. (A) Experimental outline. Cells were either (i) pulsed with a mixture of
110 nm and 215 nm labeled silk nanoparticles for 1 h and imaged or (ii) pulsed with the labeled silk nanoparticles for 1 h and then chased for 3 h
and imaged. (B) Live cell confocal ﬂuorescencemicroscopy of themixture of Alexa Fluor 488-labeled 110 nm silk nanoparticles (green) and Alexa
Fluor 594-labeled 215 nm silk nanoparticles (magenta) in RAW 264.7 cells. The scale bars are 20 mm. The white lines in the high magniﬁcation
images are used in proﬁle plots to highlight the colocalization of 110 nm and 215 nm silk nanoparticles in the cells.
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of 12 mL min1, suggesting that the fast ow rate could disrupt
the spherical morphology during particle formation and result
in a greater tendency of these particles to undergo a loose
fusion. Due to the high molecular weight of the biopolymer silk
(390 kDa), silk nanoparticle formation requires a suﬃcient
amount of organic solvent for water removal in order to form
packed silk nanoparticles. However, at a high total ow rate (i.e.
12 mL min1), one might speculate there was not enough time
for eﬃcient mixing of the two phases resulting in lower water
removal. This in turn could results in “loosely” packed silk
nanoparticles as evidenced by their irregular shape (Fig. 6) and
low yield (Fig. 2). Overall, achieving a more discrete globular
shape and uniformity required a solvent : aqueous ow rate
ratio $ 3 : 1 (and a slow ow rate). This minimum solvent to
water ratio for the formation of silk nanoparticles is consistent
with previous batch-based silk particle work.47
The nanosize range of silk nanoparticles is expected to result
in solid tumor targeting in medical applications because the
passive accumulation of nanoparticles (e.g., 100 to 200 nm) is
facilitated by the tumor pathophysiology, which includes
a leaky vasculature and impaired lymphatic clearance that
results in enhanced permeation and retention (EPR) of nano-
medicines.49 However, even EPR-mediated targeting typically
results in only a small fraction of the administered dose
reaching the tumor,50 with most medicine accumulating in
other tissues, predominantly in macrophages of the mono-
nuclear phagocytic system.51 Macrophages are intimately asso-
ciated with solid tumor development;52 therefore, the
macrophage response toward nanomedicines is an important
consideration. We have previously demonstrated that silk
nanoparticles can prime macrophages toward an M1-like
phenotype.37 Emerging evidence indicates that nanoparticle
size is important for macrophage recognition and subsequent
particle internalization.53 We therefore examined the relation-
ship of silk nanoparticle size to cytotoxicity, TNF-a release,
cellular uptake, and intracellular distribution. Cytotoxicity was
absent at the doses studied (i.e., keeping the amount of silk
constant), with no obvious size-dependent cytotoxicity (Fig. 7A).
We then selected low and high doses of 110 nm and 215 nm silk
nanoparticles and monitored TNF-a release. At the maximum
tested concentration, only a small increase was noted, but
a statistically signicant diﬀerence in TNF-a release was
observed for 215 nm silk nanoparticles when compared to
110 nm particles (Fig. 7B). Nevertheless, the biological relevance
of this diﬀerence is currently not known. Preliminary intracel-
lular traﬃcking studies showed that 110 nm and 215 nm silk
nanoparticles were both internalized by endocytosis within 1 h,
but they were localized into diﬀerent early endocytic structures.
Following a 3 h chase, the silk nanoparticles of both sizes
accumulated in late endosomal/lysosomal compartments, as
suggested by their peri-nuclear localization (Fig. 8). The
observed diﬀerences in traﬃcking at the early time point could
suggest that endocytic compartments were size-selective, as
reported previously for labeled erythrocytes.54 However, more
detailed studies are needed to better characterize the intracel-
lular traﬃcking of silk nanoparticles.
Conclusions
The use of a microuidic setup enabled the rapid, reproducible
and controllable manufacture of silk nanoparticles. The total
ow rate and the ow rate ratio were the two key process
parameters that aﬀected silk nanoparticle characteristics. A
total ow rate of 1 mL min1 and a solvent to aqueous phase
ratio of 5 : 1 provided the smallest particle size, the highest
yield, and best stability of silk nanoparticles. Subjecting the
optimized silk nanoparticles to preliminary biological assess-
ment indicated that they induced a particle-mediated macro-
phage response. In summary, microuidic-assisted
manufacturing enables the ne tuning of silk nanoparticles.
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